EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Plasma cell‐directed therapies induce profound clinical and durable responses in patients with severe or relapsed/refractory scleromyxedema

F Theves iD, C Lahuna, T Mahévas iD, S Harel, B Royer, V Lemiale, A Brignier, N Parquet, M Jachiet iD, J-D Bouaziz iD, D Elessa, B Arnulf und 1 weitere

Journal of the European Academy of Dermatology and Venereology · 2025

DOI: 10.1111/jdv.20257 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von F Theves und 12 weiteren Autor:innen. Beteiligte Einrichtung: Immuno Hematology Unit, Saint Louis Hospital, APHP, Paris, France. Hauptthemen laut MEDLINE: Scleromyxedema, Immunoglobulins, Intravenous, Plasma Cells. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Scleromyxedema (SM) is a rare skin disorder related to monoclonal gammopathy. High dose intravenous immunoglobulins (HDIVIg) are usually used as a frontline therapy with initial efficacy. However, some patients evolve with relapse, refractory state or severe extra‐cutaneous complications such as dermato‐neuro syndrome (DNS) or cardiac involvement. The objective of the study is to evaluate the use of anti‐plasma cell treatment in these patients in order to obtain a deep and durable dermatological and haematological response.

Methods

We report here eight patients treated with HDIVIg together with anti‐plasma cell therapy including: lenalidomide and dexamethasone ( n = 5); bortezomib, cyclophosphamide and dexamethasone ( n = 1); daratumumab, lenalidomide and dexamethasone ( n = 2).

Results

Combination of HDIVIg with a treatment targeting the monoclonal component led to a high level of haematological remission and drastically improved skin response with an acceptable safety profile in all patients. Moreover, HDIVIg was reduced and stopped in 4 of the 7 patients who achieved complete remission.

Conclusions

The association of lenalidomide and dexamethasone with HDIVIg could improve the treatment of relapsed or severe SM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ScleromyxedemaImmunoglobulins, IntravenousPlasma CellsHumansFemaleMiddle AgedMaleLenalidomideDexamethasoneAgedRecurrenceAdultBortezomibThalidomideAntibodies, MonoclonalCyclophosphamideTreatment Outcome

Substanzen

LenalidomideDexamethasoneImmunoglobulins, IntravenousBortezomibThalidomideAntibodies, MonoclonalCyclophosphamide

Autor:innen und Institutionen

  • Immuno Hematology Unit, Saint Louis Hospital, APHP, Paris, France.
  • Dermatology Department, Saint Louis Hospital, Paris, France.
  • Intensive Care Unit, Saint Louis Hospital, Paris, France.
  • Apheresis Unit, Saint Louis Hospital, APHP, Paris, France.

ORCID-Profile: F Theves, T Mahévas, M Jachiet, J-D Bouaziz, A Talbot

Zitieren

APA

Theves, F., Lahuna, C., Mahévas, T., Harel, S., Royer, B., Lemiale, V., Brignier, A., Parquet, N., Jachiet, M., Bouaziz, J. D., Elessa, D., Arnulf, B., & Talbot, A. (2025). Plasma cell‐directed therapies induce profound clinical and durable responses in patients with severe or relapsed/refractory scleromyxedema. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20257

Vancouver

Theves F, Lahuna C, Mahévas T, Harel S, Royer B, Lemiale V, et al. Plasma cell‐directed therapies induce profound clinical and durable responses in patients with severe or relapsed/refractory scleromyxedema. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.20257

BibTeX
@article{Theves2025,
  author = {Theves, F and Lahuna, C and Mahévas, T and Harel, S and Royer, B and Lemiale, V and Brignier, A and Parquet, N and Jachiet, M and Bouaziz, J-D and Elessa, D and Arnulf, B and Talbot, A},
  title = {Plasma cell‐directed therapies induce profound clinical and durable responses in patients with severe or relapsed/refractory scleromyxedema},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  doi = {10.1111/jdv.20257}
}
Kostenlos starten →